Market Overview - The Shanghai Composite Index closed at 4011.45 points, above the five-day moving average, with an increase of 1.07% [1] - The total trading volume of A-shares reached 1.960478 trillion yuan [1] Stock Performance - A total of 1880 A-shares have prices that surpassed the five-day moving average [1] - Stocks with significant deviation rates include: - BeiYikang (证券代: 920199) with a deviation rate of 18.85%, closing at 44.96 yuan, up 29.98% [1] - WeiSi Medical (证券代: 688580) with a deviation rate of 15.01%, closing at 58.08 yuan, up 20.00% [1] - ChengYiTong (证券代: 300430) with a deviation rate of 14.78%, closing at 23.06 yuan, up 19.98% [1] Additional Notable Stocks - Other notable stocks with high deviation rates include: - GuanHao Biological (证券代: 300238) at 14.72% [1] - DiNaiKe (证券代: 300884) at 14.64% [1] - MeiHao Medical (证券代: 301363) at 14.46% [1] - Stocks with lower deviation rates that just crossed the five-day moving average include: - ChenZhan Optoelectronics (证券代: 688767) at 12.64% [1] - SaiNuo Medical (证券代: 688108) at 12.19% [1]

证券时报·数据宝统计，截至今日上午10:28，上证综指4004.00点，收于五日均线之上，涨跌幅0.89%， A股总成交额为13939.72亿元。到目前为止，今日有1799只A股价格突破了五日均线，其中乖离率较大 的个股有倍益康、伟思医疗、诚益通等，乖离率分别为18.85%、15.01%、14.78%；天和防务、利君股 份、中船科技等个股乖离率较小，刚刚站上五日均线。 （文章来源：证券时报网） | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 五日均线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 920199 | 倍益康 | 29.98 | 11.91 | 37.83 | 44.96 | 18.85 | | 688580 | 伟思医 | 20.00 | 6.89 | 50.50 | 58.08 | 15.01 | | | 疗 | | | | | | | 300430 | 诚益通 | 19.98 | 15.71 | 20.09 | 23.06 | ...

1月5日， 脑机接口板块持续大涨，截至发稿，板块指数涨幅已超11%。 马斯克说，该设备的电极丝将直接穿过硬脑膜，而无需将其切除，此举意义重大。 编辑丨瑜见 倍益康30%涨停，美好医疗、三博脑科、熵基科技、翔宇医疗、诚益通等10股20%涨停，创新医疗、荣 泰健康、南京熊猫、三七互娱等涨停。 | 代码 | 名称 | 式唱 | 息金额 | 息而值 | 现价 | | --- | --- | --- | --- | --- | --- | | 920199 | 倍益康 | +29.98% | 1.96 Z | 30.62 G | 44.96 | | 688767 | 博拓生物 | +20.01% | 6.27 Z | 67.71 Z | 45.34 | | 301293 | 三博脑科 | +20.01% | 7.04Z | 1 45.8亿 | 70.78 | | 301363 | 美好医疗 | +20.00% | 1.98 Z | 164.2 乙 | 28.86 | | 301330 | শ্ব # 技 | +20.00% | 7.25 Z | 93.34 Z | 39.66 | | 300887 | 谱尼测试 | + ...

1月5日， 脑机接口板块持续大涨，截至发稿，板块指数涨幅已超11%。 倍益康30%涨停，美好医疗、三博脑科、熵基科技、翔宇医疗、诚益通等10股20%涨停，创新医疗、 荣泰健康、南京熊猫、三七互娱等涨停。 马斯克说，该设备的电极丝将直接穿过硬脑膜，而无需将其切除，此举意义重大。 编辑丨瑜见 | 代码 | 名称 | 涨幅量 | 息金额 | 息市值 | 现价 | | --- | --- | --- | --- | --- | --- | | 920199 | 倍益康 | +29.98% | 1.96 Z | 30.62 乙 | 44.96 | | 688767 | 博拓生物 | +20.01% | 6.27 Z | 67.71 Z | 45.34 | | 301293 | 三博脑科 | +20.01% | 7.04 Z | 145.8亿 | 70.78 | | 301363 | 美好医疗 | +20.00% | 1.98 乙 | 164.2 乙 | 28.86 | | 301330 | 腐基科技 | +20.00% | 7.25 Z | 93.34 乙 | 39.66 | | 300887 | 谱尼测试 | +20 ...

Group 1 - The brain-computer interface concept has seen significant market activity, with multiple stocks experiencing substantial gains [1] - Companies such as Botao Bio and Aerospace Changfeng have reached their daily price limit, indicating strong investor interest [1] - Nearly 20 stocks, including Beiyikang and Sanbo Brain Science, have also hit their daily price limit, showcasing a broad rally in the sector [1] Group 2 - Other notable performers include Guanhao Bio, Dineike, Zhongke Information, Hanwei Technology, and Daoshi Technology, all of which have seen stock increases exceeding 10% [1]

证券日报网讯12月29日，诚益通（300430）在互动平台回答投资者提问时表示，公司脑机接口业务方 面，近期公司控股子公司北京脑连科技有限公司获得了"脑电采集装置和脑电采集设备"发明专利，同 时，公司也在抓紧推进脑电采集相关医疗器械产品注册证的申报工作，2026年将取得相关注册证书，请 关注公司披露信息及脑连科技公众号进展。 ...

Investment Rating - The report maintains an "Overweight" rating for the biomedical sector [4] Core Insights - The brain-computer interface (BCI) industry is at a critical stage of policy support, rapid technological iteration, and accelerated commercialization, with a global market approaching $10 billion [3][9] - The industry is driven by both policy and technology, with significant investments from major countries, including approximately $4.5 billion from the U.S. BRAIN Initiative and hundreds of billions in China [1][51] - The medical application of BCI technology is the most mature segment, focusing on neurorehabilitation, functional replacement, and disease treatment, with a dual growth curve emerging from medical and consumer applications [2][45] Summary by Sections Industry Overview - BCI is defined as a technology that creates a communication channel between the brain and external devices, enabling direct information exchange [16] - BCI can be categorized into invasive, semi-invasive, and non-invasive types, each with distinct applications in medical rehabilitation, consumer interaction, and military use [17][19] - The global BCI market is projected to grow from $1.2 billion in 2019 to approximately $7.63 billion by 2029, with a compound annual growth rate (CAGR) exceeding 13% [24] Policy Guidance - Major countries have launched BCI-related initiatives, with the U.S. and EU leading in funding and research efforts [52][53] - China's "Brain Plan" aims to enhance brain science and BCI technology, with significant funding expected in the coming years [54][57] Clinical Applications - The medical sector is the primary focus for BCI applications, with significant demand driven by conditions such as stroke and disabilities [45][48] - Clinical trials for BCI products are accelerating globally, with notable advancements in both invasive and non-invasive technologies [3][19] Industry Progress - The report highlights the competitive landscape, noting that while foreign companies like Neuralink and Synchron have a head start, domestic firms are making significant strides in key areas such as flexible electrodes and real-time language decoding [2][4][30] - The BCI industry is characterized by a complex supply chain, with upstream components like electrodes and chips, midstream product supply, and downstream applications across various sectors [30][33] Investment Recommendations - Investors are advised to focus on companies with strong technological barriers and clinical application capabilities, particularly in the medical sector, which is the most developed area for BCI commercialization [3][9] - Specific companies to watch include medical scene integrators and leaders in invasive/semi-invasive technologies, such as Xiangyu Medical, Weisi Medical, and Brain Tiger Technology [3][9]

证券代码：300430 证券简称：诚益通 公告编号：2025-056 北京诚益通控制技术集团股份有限公司 关于为上市公司及子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、融资情况概述 北京诚益通控制技术集团股份有限公司（以下简称"公司"或"诚益通"） 于 2025 年 4 月 23 日召开了第五届董事会第十一次会议，会议审议通过了《关于 预计 2025 年度公司及合并范围内公司申请银行综合授信及项目贷款额度的议案》 《关于预计 2025 年度公司及合并范围内公司担保额度的议案》（公告编号： 2025-020、021），同意公司、子公司及合并报表范围内的子公司、孙公司向银 行及其他金融机构申请合计额度不超过人民币 13.79 亿元的授信等业务，在授权 期限内额度可循环使用，担保总额合计不超过 13.19 亿元。上述议案同时由 2025 年 5 月 15 日召开的 2024 年度股东大会审议通过。 二、融资进展情况 近期，公司与江苏银行股份有限公司北京分行（以下简称"江苏银行"）签 署《最高额保证合同》，同意为北京诚益通科技有限公司（ ...

（文章来源：证券日报） 证券日报网讯 12月22日晚间，诚益通发布公告称，公司实际控制人梁学贤先生本次解除质押46.64万 股，占其所持股份2.53%，占公司总股本0.17%，质权人为北京中关村科技融资担保有限公司，质押到 期日为2025年12月18日。 ...

诚益通公告，公司实际控制人梁学贤解除质押46.64万股，占其所持股份比例2.53%，占公司总股本比例 0.17%。 ...